Brief Summary
This study is collecting and storing malignant, borderline malignant neoplasms, and related biological samples from young patients with cancer. Collecting and storing samples of tumor tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help the study of cancer in the future.
Brief Title
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
Detailed Description
OBJECTIVES:
I. Collect malignant, borderline malignant neoplasms, and related biological specimens from Children's Oncology Group institutions for cases in which there is no disease-specific biologic protocol.
II. Provide a repository for long-term storage of malignant, borderline malignant neoplasms, and related biological specimens from these patients.
III. Make specimens available to qualified researchers to understand the biology of cancer in these patients.
OUTLINE:
Tumor tissue samples, blood, and bone marrow aspirates are collected and stored for future analysis.
I. Collect malignant, borderline malignant neoplasms, and related biological specimens from Children's Oncology Group institutions for cases in which there is no disease-specific biologic protocol.
II. Provide a repository for long-term storage of malignant, borderline malignant neoplasms, and related biological specimens from these patients.
III. Make specimens available to qualified researchers to understand the biology of cancer in these patients.
OUTLINE:
Tumor tissue samples, blood, and bone marrow aspirates are collected and stored for future analysis.
Categories
Completion Date
Completion Date Type
Actual
Conditions
Acute Undifferentiated Leukemia
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Childhood Acute Lymphoblastic Leukemia
Childhood Acute Myeloid Leukemia
Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Childhood Solid Neoplasm
Chronic Lymphocytic Leukemia
Hairy Cell Leukemia
Juvenile Myelomonocytic Leukemia
Mast Cell Leukemia
Neoplasm of Uncertain Malignant Potential
Prolymphocytic Leukemia
Secondary Acute Myeloid Leukemia
T-Cell Large Granular Lymphocyte Leukemia
Eligibility Criteria
Inclusion Criteria:
* Meets any of the following criteria:
* Diagnosed with primary neoplasm
* Developed a second malignant neoplasm
* Any diagnoses having an ICD-O Morphology Code ending in 1, 2, or 3 as listed in the International Classification of Disease for Oncology, Third Edition
* Must have biological specimens including solid tumors and leukemias available
* Solid tumors meeting the following criteria:
* Snap frozen primary tumor OR OCT embedded primary tumor OR formalin fixed (block or tissue in formalin) primary tumor AND at least 10 unstained paraffin slides for NIH Mandated QC (tumors that have undergone central pathology review are allowed)
* Slides for pathology review (instead of slides for QC) are required for patients with rare tumors
* Pleural fluid or cytologic specimens meeting the following criteria:
* At least 1 mL of fluid and at least 2 unstained cytospin slides (or 2 unstained smears)
* Slides for pathology review (instead of slides for QC) are required for patients with rare tumors
* ALL/AML
* 3-6 mL of bone marrow aspirate and 10 mL of whole blood
* Not eligible for disease-specific biology or banking protocol
* Meets any of the following criteria:
* Diagnosed with primary neoplasm
* Developed a second malignant neoplasm
* Any diagnoses having an ICD-O Morphology Code ending in 1, 2, or 3 as listed in the International Classification of Disease for Oncology, Third Edition
* Must have biological specimens including solid tumors and leukemias available
* Solid tumors meeting the following criteria:
* Snap frozen primary tumor OR OCT embedded primary tumor OR formalin fixed (block or tissue in formalin) primary tumor AND at least 10 unstained paraffin slides for NIH Mandated QC (tumors that have undergone central pathology review are allowed)
* Slides for pathology review (instead of slides for QC) are required for patients with rare tumors
* Pleural fluid or cytologic specimens meeting the following criteria:
* At least 1 mL of fluid and at least 2 unstained cytospin slides (or 2 unstained smears)
* Slides for pathology review (instead of slides for QC) are required for patients with rare tumors
* ALL/AML
* 3-6 mL of bone marrow aspirate and 10 mL of whole blood
* Not eligible for disease-specific biology or banking protocol
Inclusion Criteria
Inclusion Criteria:
* Meets any of the following criteria:
* Diagnosed with primary neoplasm
* Developed a second malignant neoplasm
* Any diagnoses having an ICD-O Morphology Code ending in 1, 2, or 3 as listed in the International Classification of Disease for Oncology, Third Edition
* Must have biological specimens including solid tumors and leukemias available
* Solid tumors meeting the following criteria:
* Snap frozen primary tumor OR OCT embedded primary tumor OR formalin fixed (block or tissue in formalin) primary tumor AND at least 10 unstained paraffin slides for NIH Mandated QC (tumors that have undergone central pathology review are allowed)
* Slides for pathology review (instead of slides for QC) are required for patients with rare tumors
* Pleural fluid or cytologic specimens meeting the following criteria:
* At least 1 mL of fluid and at least 2 unstained cytospin slides (or 2 unstained smears)
* Slides for pathology review (instead of slides for QC) are required for patients with rare tumors
* ALL/AML
* 3-6 mL of bone marrow aspirate and 10 mL of whole blood
* Not eligible for disease-specific biology or banking protocol
* Meets any of the following criteria:
* Diagnosed with primary neoplasm
* Developed a second malignant neoplasm
* Any diagnoses having an ICD-O Morphology Code ending in 1, 2, or 3 as listed in the International Classification of Disease for Oncology, Third Edition
* Must have biological specimens including solid tumors and leukemias available
* Solid tumors meeting the following criteria:
* Snap frozen primary tumor OR OCT embedded primary tumor OR formalin fixed (block or tissue in formalin) primary tumor AND at least 10 unstained paraffin slides for NIH Mandated QC (tumors that have undergone central pathology review are allowed)
* Slides for pathology review (instead of slides for QC) are required for patients with rare tumors
* Pleural fluid or cytologic specimens meeting the following criteria:
* At least 1 mL of fluid and at least 2 unstained cytospin slides (or 2 unstained smears)
* Slides for pathology review (instead of slides for QC) are required for patients with rare tumors
* ALL/AML
* 3-6 mL of bone marrow aspirate and 10 mL of whole blood
* Not eligible for disease-specific biology or banking protocol
Gender
All
Gender Based
false
Healthy Volunteers
No
Last Update Post Date
Last Update Post Date Type
Actual
Last Update Submit Date
Maximum Age
30 Years
NCT Id
NCT00898079
Org Class
Network
Org Full Name
Children's Oncology Group
Org Study Id
ABTR01B1
Overall Status
Completed
Primary Completion Date
Primary Completion Date Type
Actual
Official Title
A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
Primary Outcomes
Outcome Measure
Repository of malignant, borderline malignant neoplasms, and related biological specimens
Outcome Time Frame
Baseline
Secondary Ids
Secondary Id
NCI-2009-00324
Secondary Id
CDR0000271415
Secondary Id
COG-ABTR01B1
Secondary Id
ABTR01B1
Secondary Id
ABTR01B1
Secondary Id
U10CA098543
Secondary Id
UG1CA189958
Start Date
Start Date Type
Actual
Status Verified Date
First Post Date
First Post Date Type
Estimated
First Submit Date
First Submit QC Date
Std Ages
Child
Adult
Maximum Age Number (converted to Years and rounded down)
30
Minimum Age Number (converted to Years and rounded down)
0
Investigators
Investigator Type
Principal Investigator
Investigator Name
Lisa Gennarini
Investigator Email
lfigueir@montefiore.org
Investigator Phone